Blowey D L, Balfe J W, Gupta I, Gajaria M M, Koren G
Division of Clinical Pharmacology, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
Am J Kidney Dis. 1996 Jul;28(1):132-6. doi: 10.1016/s0272-6386(96)90142-0.
Recurrent intradialytic hypotension, a complication of hemodialysis, is a consequence of an inadequate compensatory response or a paradoxic response to ultrafiltration-induced volume reduction. We report the use of midodrine, an alpha agonist, in an 18-year-old man with Bardet-Biedl syndrome and recurrent intradialytic hypotension. The clinical features of the intradialytic hypotensive spells are consistent with a paradoxic withdrawal of sympathetic activity, although an underlying abnormality in autonomic dysfunction cannot be excluded. Midodrine significantly increased the intradialytic blood pressure and decreased the intradialytic hypotensive episodes requiring intervention. The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function. However, the prolonged terminal half-life for the active metabolite, de-glymidodrine, warrants careful administration in patients with renal failure.
透析中反复发生的低血压是血液透析的一种并发症,是对超滤引起的容量减少的代偿反应不足或反常反应的结果。我们报告了一名18岁患有巴德-比德尔综合征且透析中反复发生低血压的男性使用α受体激动剂米多君的情况。透析中低血压发作的临床特征与交感神经活动的反常减退一致,尽管不能排除自主神经功能障碍的潜在异常。米多君显著提高了透析中的血压,并减少了需要干预的透析中低血压发作次数。前体药物米多君及其活性代谢产物去甘米多君在该终末期肾病患者中的药代动力学特征与肾功能正常患者报告的情况相近。然而,活性代谢产物去甘米多君的终末半衰期延长,因此在肾衰竭患者中用药时需谨慎。